Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ADCT Stock Forecast 2026-2027
$1.25
Current Price
$158.99M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to ADCT Price Targets
+700.0%
To High Target of $10.00
+140.0%
To Median Target of $3.00
+60.0%
To Low Target of $2.00
ADCT Price Momentum
-2.3%
1 Week Change
+19.0%
1 Month Change
-61.5%
1 Year Change
-64.6%
Year-to-Date Change
-74.9%
From 52W High of $4.98
+60.3%
From 52W Low of $0.78
📊 TOP ANALYST CALLS
Did ADCT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ADC Therapeutics is one of their latest high-conviction picks.
Latest ADCT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ADCT has a bullish consensus with a median price target of $3.00 (ranging from $2.00 to $10.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $1.25, the median forecast implies a 140.0% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Leonid Timashev at RBC Capital, suggesting a 60.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADCT Analyst Ratings
3
Buy
2
Hold
0
Sell
ADCT Price Target Range
Low
$2.00
Average
$3.00
High
$10.00
Current: $1.25
Latest ADCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $N/A |
| Jun 4, 2026 | RBC Capital | Leonid Timashev | Sector Perform | Downgrade | $2.00 |
| May 5, 2026 | RBC Capital | Outperform | Reiterates | $N/A | |
| May 5, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 16, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 13, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Jun 20, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Jun 13, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| May 15, 2025 | RBC Capital | Outperform | Reiterates | $N/A | |
| Mar 31, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Feb 24, 2025 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Jan 6, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 12, 2024 | Guggenheim | Buy | Reiterates | $N/A | |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 8, 2024 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Aug 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2024 | RBC Capital | Outperform | Reiterates | $N/A |
ADC Therapeutics SA (ADCT) Competitors
The following stocks are similar to ADC Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ADCT
ADC Therapeutics
mkt cap
164.08M
ADC Therapeutics SA (ADCT) Financial Data
ADC Therapeutics SA has a market capitalization of $158.99M with a P/E ratio of -1.1x. The company generates $79.18M in trailing twelve-month revenue with a -173.0% profit margin.
Revenue growth is -9.5% quarter-over-quarter, while maintaining an operating margin of -121.1% and return on equity of +76.7%.
Valuation Metrics
Market Cap
$158.99M
Enterprise Value
$364.24M
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
-9.5%
Gross Margin
+82.7%
Operating Margin
-121.1%
Net Margin
-173.0%
EPS Growth
-9.5%
Financial Health
Cash/Price Ratio
+145.3%
Current Ratio
4.1x
Debt/Equity
-2.0x
ROE
+76.7%
ROA
-22.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ADC Therapeutics SA (ADCT) Business Model
About ADC Therapeutics SA
What They Do
Develops antibody-drug conjugates for cancer treatment.
Business Model
ADC Therapeutics generates revenue by developing and commercializing innovative antibody-drug conjugates (ADCs) aimed at treating hematological cancers and solid tumors. The company focuses on addressing unmet medical needs through its pipeline of therapeutics, which are in various stages of clinical trials, and collaborates with other research entities to enhance its drug development efforts.
Additional Information
Headquartered in Switzerland, ADC Therapeutics targets a range of cancers, including aggressive blood cancers like non-Hodgkin lymphoma. The company's commitment to scientific innovation positions it as a significant player in the biopharmaceutical industry, with the potential to introduce breakthrough therapies that could reshape oncology treatment.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
188
CEO
Dr. Ameet Mallik M.B.A., M.S.
Country
Switzerland
IPO Year
2020
Website
www.adctherapeutics.comADC Therapeutics SA (ADCT) Latest News & Analysis
Latest News
Quick Summary
ADC Therapeutics SA granted options to purchase 17,000 common shares to a new employee on July 1, 2026, as an inducement for their employment.
Why It Matters
The grant of stock options indicates ADC Therapeutics' commitment to attracting talent, which could enhance innovation and growth, potentially impacting future profitability and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
14 days ago
Quick Summary
ADC Therapeutics has completed enrollment in the LOTIS-7 trial, dosing 100 patients with r/r DLBCL with ZYNLONTA® and glofitamab. Full data is expected in Q4 2026.
Why It Matters
Completion of the LOTIS-7 trial enrollment signals potential advancements in cancer treatment, impacting ADC Therapeutics' market position and future revenues, crucial for investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
19 days ago
Quick Summary
Pomerantz LLP is investigating claims for ADC Therapeutics SA (NYSE: ADCT) investors. Interested parties should contact Danielle Peyton for further information.
Why It Matters
The investigation by Pomerantz LLP signals potential legal issues for ADC Therapeutics, which may affect stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ADC Therapeutics plans a 17% workforce reduction to save $10M annually, focusing on key initiatives and upcoming regulatory milestones, including LOTIS-5 sBLA and LOTIS-7 data by 2026.
Why It Matters
The workforce reduction aims to save $10M annually, enhancing financial stability. Focus on key initiatives may drive future growth, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
28 days ago
Quick Summary
Pomerantz LLP is investigating claims for ADC Therapeutics SA investors. Interested parties should contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Why It Matters
Pomerantz LLP's investigation into ADC Therapeutics may signal potential legal issues or financial risks, prompting investor scrutiny and possible impacts on stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ADC Therapeutics shares fell nearly 53% in premarket trading after a late-stage study revealed increased mortality among patients treated with its blood cancer drug, despite achieving its primary endpoint.
Why It Matters
ADC Therapeutics' stock drop reflects investor concerns over safety despite achieving primary study goals, signaling potential regulatory and market challenges for its blood cancer drug.
Source: Reuters
Market Sentiment:
Negative
Frequently Asked Questions About ADCT Stock
What is ADC Therapeutics SA's (ADCT) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, ADC Therapeutics SA (ADCT) has a median price target of $3.00. The highest price target is $10.00 and the lowest is $2.00.
Is ADCT stock a good investment in 2027?
According to current analyst ratings, ADCT has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADCT stock?
Wall Street analysts predict ADCT stock could reach $3.00 in the next 12 months. This represents a 140.0% increase from the current price of $1.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ADC Therapeutics SA's business model?
ADC Therapeutics generates revenue by developing and commercializing innovative antibody-drug conjugates (ADCs) aimed at treating hematological cancers and solid tumors. The company focuses on addressing unmet medical needs through its pipeline of therapeutics, which are in various stages of clinical trials, and collaborates with other research entities to enhance its drug development efforts.
What is the highest forecasted price for ADCT ADC Therapeutics SA?
The highest price target for ADCT is $10.00 from at , which represents a 700.0% increase from the current price of $1.25.
What is the lowest forecasted price for ADCT ADC Therapeutics SA?
The lowest price target for ADCT is $2.00 from Leonid Timashev at RBC Capital, which represents a 60.0% increase from the current price of $1.25.
What is the overall ADCT consensus from analysts for ADC Therapeutics SA?
The overall analyst consensus for ADCT is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are ADCT stock price projections?
Stock price projections, including those for ADC Therapeutics SA, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 6:34 PM UTC